Drugnews

What are the BMS–BioNTech BNT327 deal terms?

On June 2, 2025, Bristol Myers Squibb and BioNTech announced a BNT327 partnership with $1.5 billion upfront, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in additional milestones. These components sum to a potential $11.1 billion; BNT327 targets PD-L1 and VEGF-A, so it should be distinguished from PD-1×VEGF candidates.

Updated

Announced consideration in US dollars
MeasureReported resultBasis
Upfront payment$1.5 billionAt the partnership outset
Non-contingent payments$2 billionAnniversary payments through 2028
Potential milestonesUp to $7.6 billionAdditional conditional payments
Potential totalUp to $11.1 billionCalculated: upfront plus anniversary payments plus milestones

Ivonescimab after the FDA letter

On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.

November 17, 2026 analysis

Sources

Read the full analysis

FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026